Trial Profile

A First-in-Human, Open-label, Phase 1 Dose-Escalation Study of 609A in Subjects With Locally Advanced/Metastatic Solid Tumors in China

Status: Recruiting

Phase of Trial: Phase I

Latest Information Update: 05 Sep 2022

Price :

$35 ^*

Note:

Adis is an information provider.
Final gross price and currency may vary according to local VAT and billing address.
Your purchase entitles you to full access to the information contained in our trial profile at the time of purchase.
A link to download a PDF version of the trial profile will be included in your email receipt.

At a glance

Drugs 609 A (Primary)
Indications Solid tumours
Focus Adverse reactions; First in man
Sponsors Sunshine Guojian Pharmaceutical

Most Recent Events

02 Aug 2020 Planned End Date changed from 24 Jun 2020 to 30 Dec 2020.
02 Aug 2020 Planned primary completion date changed from 24 Jun 2020 to 24 Dec 2020.
02 Aug 2020 Status changed from not yet recruiting to recruiting.

You need to be a logged in or subscribed to view this content

If your organization or you do not have a subscription, try one of the following:

Contacting your organization’s admin about adding this content to your AdisInsight subscription
Buying a PDF version of any individual profile
Request a free trial (opens in a new window)

If your organization has a subscription, there are several access options, even while working remotely:

Working within your organization’s network
Login with username/password or try to access via your institution
Persisted access using your organization’s identifier stored in your user browser for 90 days

For assistance, contact us at asktheexpert.adisinsight@springer.com